FDA's Biologics Naming Plan: Industry Wants 'Memorable' Suffixes

Random letter-based suffixes will make it difficult for prescribers and patients to identify a given product, biopharma companies say, requesting that suffixes be derived from the license-holder's name; GPhA, Federal Trade Commission say FDA plan for distinguishable names will create confusion and uncertainty.